Free Trial

Immunic (IMUX) Competitors

Immunic logo
$0.71 +0.02 (+3.27%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$0.71 0.00 (0.00%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMUX vs. FHTX, TRDA, LFCR, TSVT, ALLO, ADCT, AMRN, INZY, PVLA, and ANNX

Should you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Foghorn Therapeutics (FHTX), Entrada Therapeutics (TRDA), Lifecore Biomedical (LFCR), 2seventy bio (TSVT), Allogene Therapeutics (ALLO), ADC Therapeutics (ADCT), Amarin (AMRN), Inozyme Pharma (INZY), Palvella Therapeutics (PVLA), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry.

Immunic vs. Its Competitors

Foghorn Therapeutics (NASDAQ:FHTX) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Foghorn Therapeutics presently has a consensus target price of $12.13, suggesting a potential upside of 144.95%. Immunic has a consensus target price of $11.60, suggesting a potential upside of 1,526.93%. Given Immunic's stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than Foghorn Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foghorn Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.13
Immunic
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.25

Immunic has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -342.23%. Foghorn Therapeutics' return on equity of 0.00% beat Immunic's return on equity.

Company Net Margins Return on Equity Return on Assets
Foghorn Therapeutics-342.23% N/A -27.28%
Immunic N/A -326.95%-181.34%

Foghorn Therapeutics has a beta of 3.05, suggesting that its stock price is 205% more volatile than the S&P 500. Comparatively, Immunic has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.

In the previous week, Foghorn Therapeutics had 1 more articles in the media than Immunic. MarketBeat recorded 2 mentions for Foghorn Therapeutics and 1 mentions for Immunic. Foghorn Therapeutics' average media sentiment score of 1.13 beat Immunic's score of 0.87 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Foghorn Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immunic
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Foghorn Therapeutics has higher revenue and earnings than Immunic. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Foghorn Therapeutics$22.60M12.21-$86.62M-$1.36-3.64
ImmunicN/AN/A-$100.51M-$1.23-0.58

Summary

Foghorn Therapeutics beats Immunic on 9 of the 15 factors compared between the two stocks.

Get Immunic News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMUX vs. The Competition

MetricImmunicMED IndustryMedical SectorNASDAQ Exchange
Market Cap$66.15M$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E Ratio-0.5821.3126.2319.90
Price / SalesN/A278.47413.23113.66
Price / CashN/A41.4736.1356.90
Price / Book3.577.518.045.38
Net Income-$100.51M-$55.05M$3.15B$248.50M
7 Day Performance0.37%2.07%1.44%2.04%
1 Month Performance-2.38%4.84%3.62%4.84%
1 Year Performance-37.73%5.37%34.68%20.23%

Immunic Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMUX
Immunic
2.6203 of 5 stars
$0.71
+3.3%
$11.60
+1,526.9%
-38.0%$66.15MN/A-0.5870
FHTX
Foghorn Therapeutics
2.0446 of 5 stars
$4.88
+3.3%
$12.13
+148.7%
-9.0%$269.22M$22.60M-3.55120News Coverage
TRDA
Entrada Therapeutics
3.3758 of 5 stars
$7.08
-0.6%
$25.67
+262.5%
-48.1%$268.72M$210.78M8.74110Trending News
Insider Trade
LFCR
Lifecore Biomedical
1.6188 of 5 stars
$7.25
+4.5%
$8.00
+10.3%
+70.3%$268.10M$128.26M-4.99690
TSVT
2seventy bio
N/A$5.00
flat
$5.00
N/A$266.15M$48.37M-2.69440
ALLO
Allogene Therapeutics
3.4292 of 5 stars
$1.22
-1.2%
$8.44
+595.0%
-44.4%$265.76M$20K-0.99310Gap Down
ADCT
ADC Therapeutics
1.6753 of 5 stars
$2.67
-3.8%
$7.75
+190.8%
-19.0%$265.31M$70.84M-1.84310Gap Down
AMRN
Amarin
0.7503 of 5 stars
$12.60
+0.5%
$7.00
-44.4%
+18.1%$260.95M$228.61M-3.46360
INZY
Inozyme Pharma
3.4168 of 5 stars
$4.00
+0.1%
$11.75
+194.1%
N/A$257.93MN/A-2.3650News Coverage
PVLA
Palvella Therapeutics
3.2158 of 5 stars
$23.19
+5.2%
$46.29
+99.6%
N/A$256.48M$42.81M-1.92N/A
ANNX
Annexon
2.2575 of 5 stars
$2.34
-1.9%
$12.50
+435.3%
-38.4%$256.17MN/A-1.9860News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:IMUX) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners